Bio-Path Stock Forecast, Price & News

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Bio-Path in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Bio-Path stock.
View analyst ratings for Bio-Path or view top-rated stocks.

Wall Street analysts have given Bio-Path a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Bio-Path wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Bio-Path saw a increase in short interest in February. As of February 12th, there was short interest totaling 474,200 shares, an increase of 88.6% from the January 28th total of 251,400 shares. Based on an average daily trading volume, of 1,970,000 shares, the short-interest ratio is presently 0.2 days.
View Bio-Path's Short Interest.

Bio-Path is scheduled to release its next quarterly earnings announcement on Friday, March 5th 2021.
View our earnings forecast for Bio-Path.

Bio-Path Holdings, Inc. (NASDAQ:BPTH) released its quarterly earnings data on Thursday, November, 19th. The company reported ($0.80) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.83) by $0.03.
View Bio-Path's earnings history.

Bio-Path's stock was trading at $4.75 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, BPTH stock has increased by 28.4% and is now trading at $6.10.
View which stocks have been most impacted by COVID-19.

Bio-Path shares reverse split before market open on Friday, January 18th 2019. The 1-20 reverse split was announced on Friday, January 18th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, January 17th 2019. An investor that had 100 shares of Bio-Path stock prior to the reverse split would have 5 shares after the split.

1 brokerages have issued 12 month target prices for Bio-Path's shares. Their forecasts range from $10.00 to $10.00. On average, they anticipate Bio-Path's stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 63.9% from the stock's current price.
View analysts' price targets for Bio-Path or view top-rated stocks among Wall Street analysts.

Some companies that are related to Bio-Path include DiaMedica Therapeutics (DMAC), Clearside Biomedical (CLSD), Sierra Oncology (SRRA), OncoSec Medical (ONCS), Aquestive Therapeutics (AQST), Seelos Therapeutics (SEEL), Adamas Pharmaceuticals (ADMS), Eyenovia (EYEN), Hepion Pharmaceuticals (HEPA), Biofrontera (BFRA), Aptevo Therapeutics (APVO), ASLAN Pharmaceuticals (ASLN), GlycoMimetics (GLYC), Citius Pharmaceuticals (CTXR) and ContraFect (CFRX).
View all of BPTH's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Path investors own include NVIDIA (NVDA), Palatin Technologies (PTN), Micron Technology (MU), Advanced Micro Devices (AMD), Amarin (AMRN), (CGC), Trevena (TRVN), Energy Transfer (ET), Anavex Life Sciences (AVXL) and Biocept (BIOC).

Bio-Path trades on the NASDAQ under the ticker symbol "BPTH."

Bio-Path's stock is owned by many different retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (1.71%) and Virtu Financial LLC (0.48%).
View institutional ownership trends for Bio-Path.

BPTH stock was bought by a variety of institutional investors in the last quarter, including Virtu Financial LLC, and Renaissance Technologies LLC.
View insider buying and selling activity for Bio-Path or or view top insider-buying stocks.

Shares of BPTH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of BPTH stock can currently be purchased for approximately $6.10.

Bio-Path has a market capitalization of $42.38 million. The company earns $-8,600,000.00 in net income (profit) each year or ($3.24) on an earnings per share basis.

Bio-Path employs 9 workers across the globe.

The official website for Bio-Path is www.biopathholdings.com.

Bio-Path is headquartered at 4710 BELLAIRE BOULEVARD SUITE 210, BELLAIRE TX, 77401.

Bio-Path's mailing address is 4710 BELLAIRE BOULEVARD SUITE 210, BELLAIRE TX, 77401. The company can be reached via phone at 832-742-1357 or via email at [email protected]